GlaxoSmithKline's OTC Garage Sale Includes alli, FiberChoice
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline includes the alli weight-loss brand in its planned divestment of international OTCs worth about $813 million in 2010 sales, or 10% of the firm's total Consumer Healthcare business.
You may also be interested in...
Insight Acquires Monistat In Third Deal With McNeil For Women’s OTC Drugs
Insight Pharmaceutical expanded its women’s health care footprint with the acquisition of the Monistat North American portfolio from McNeil Consumer Healthcare.
Education About NRT Safety Overcomes Smokers’ Cost Barrier – Study
Drug firms could educate consumers about the safety and efficacy of nicotine-replacement therapies to show the products’ value, according to recent research.
GSK Urges Regulatory Changes To Pull EU Market From Doldrums
The time appears right for Rx-to-OTC switches as European Union members struggle to control expanding health budgets in the face of aging populations and the continuing global economic crisis.